CARCINOMA, NON-SMALL-CELL LUNG

This study tests a vaccine made from lung cancer cells, combined with an immune-boosting drug (N-803), to see if it can prevent non-small cell lung cancer from returning after surgery. About 30 adults with no signs of cancer after surgery will receive the vaccine as shots under t…

This study tested whether the drug durvalumab can help people with advanced, inoperable lung cancer (Stage III) keep their cancer from growing after they finish chemotherapy and radiation. About 400 adults who had not gotten worse after initial treatment received either durvaluma…

This study tests whether a newer targeted drug, lorlatinib, works better than the current standard drug, crizotinib, for people with advanced ALK-positive non-small cell lung cancer who have not had prior treatment. About 296 participants will receive either lorlatinib or crizoti…

This study tests a new drug, entrectinib, against the current standard drug, crizotinib, in people with a specific type of advanced lung cancer (ROS1-positive). About 220 participants will take one of the two pills daily. The goal is to see which drug works better at stopping the…

This early-stage study tests an experimental drug called SGN-MesoC2 in people with advanced solid tumors (like lung, ovarian, or pancreatic cancer) that have not responded to standard treatments. The drug is designed to attach to cancer cells and kill them. The main goals are to …

This study tests whether adding the drugs pembrolizumab and olaparib to standard chemoradiation helps people with stage III non-small cell lung cancer that cannot be surgically removed. About 870 participants will receive either pembrolizumab with or without olaparib after chemor…

This study tests a new drug called THIO given before the immunotherapy cemiplimab in people with advanced non-small cell lung cancer whose disease worsened after initial treatment. The goal is to see if this sequence can make tumors respond again to immunotherapy. About 227 adult…

This study tests whether adding sacituzumab govitecan to the immunotherapy drug pembrolizumab helps people with a specific type of advanced lung cancer live longer or keep their cancer from growing, compared to pembrolizumab alone. About 614 adults whose tumors have high levels o…

This study tests a combination of two targeted drugs, amivantamab and capmatinib, in people with advanced non-small cell lung cancer that has spread. The goal is to find the best dose and see if the drugs can shrink tumors. About 57 adults with specific genetic changes (MET mutat…

This study tests a targeted drug called osimertinib (Tagrisso) in 30 people with advanced EGFR-mutant non-small cell lung cancer who have not had this type of treatment before. The main goal is to understand why the drug stops working by comparing tumor samples taken before and a…

This study tests a combination of two drugs, amivantamab and cetrelimab, in people with advanced non-small cell lung cancer that has spread. The goal is to find the best dose and see if the combination can shrink tumors. About 71 participants will take part, and the study tracks …

This study tests the drug lorlatinib in people with a specific type of lung cancer (ALK-positive) that has spread to the brain or the lining of the brain and spinal cord. The goal is to see how well the drug shrinks these brain tumors. About 41 adults will take part, and the stud…

This program gives patients with serious non-small cell lung cancer access to the drug capmatinib when no other treatments are available and they cannot join a clinical trial. It is for people whose doctors have requested the drug and who have no satisfactory alternative therapy.…

This study tests whether the drug selpercatinib can delay cancer return in people with early-stage non-small cell lung cancer that has a specific genetic change (RET fusion). Participants who have already had surgery or radiation will receive either selpercatinib or a placebo for…

This study looks back at the experiences of 35 adults with a specific type of advanced lung cancer (ROS1-positive NSCLC) that had stopped responding to other treatments. All participants took lorlatinib pills at home until their cancer progressed. Researchers will analyze how lon…

This study is for people with a specific type of advanced lung cancer (EGFRm NSCLC) that has been treated before. It tests new combinations of drugs to see if they are safe and can shrink tumors. About 43 adults are taking part, and the goal is to better control the disease, not …

This study tests whether giving a specific immunotherapy drug again, along with another drug and targeted radiation, can help control advanced non-small cell lung cancer. About 54 people whose cancer stopped responding to standard immunotherapy will receive this combination. The …

This study tested a drug called tisotumab vedotin, alone or with other cancer medicines, in 350 people with advanced colorectal, lung, pancreatic, or head and neck cancers that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors and …

This study tests whether adding high-dose vitamin C (ascorbate) to the usual treatment of radiation and chemotherapy (carboplatin and paclitaxel) helps control non-small cell lung cancer. About 43 participants received this combination therapy. The goal is to see if the vitamin C…

This study tests whether adding two targeted drugs (amivantamab and lazertinib) to standard chemotherapy can help people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) live longer without their cancer growing. The study includes 776 adults …

This early-phase study tests a new drug called KFA115, alone or with pembrolizumab, in people with advanced cancers like lung, melanoma, and kidney cancer. The main goal is to find a safe dose and understand side effects. About 126 participants will take part to see if the treatm…

This early-phase study tests an experimental pill called LOXO-260 in about 70 adults whose cancers (such as certain lung or thyroid cancers) have a specific RET gene change and have stopped responding to other targeted therapies. The main goals are to find a safe dose and to see …

This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy before and after surgery can help people with early-stage (stage II to IIIB) non-small cell lung cancer live longer without the cancer coming back. About 461 participants will receive either…

This study tests whether a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus chemotherapy works better than the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-small cell lung cancer that has specific gene mutations (S…

This study tests a new drug called Dato-DXd in Chinese patients with advanced non-small-cell lung cancer or triple-negative breast cancer that has spread or stopped responding to treatment. The drug works by attaching to cancer cells and blocking their growth. About 119 participa…

This study tests an experimental drug called disitamab vedotin in people with advanced head and neck, lung, endometrial, or ovarian cancers that have a marker called HER2. The drug is designed to stick to cancer cells and kill them. About 120 participants will receive the drug ev…

This study tests a drug called JDQ443, alone or with other treatments, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drug is safe and can shrink tumors. About 344 adults with lung, colorectal, or other cancers who have tri…

This study tests a combination of two drugs, tucatinib and trastuzumab, in people with advanced solid tumors that have HER2 alterations. The goal is to see if the treatment can shrink or control the cancer. About 217 participants with various cancer types, including lung, uterine…

This study tests a new experimental drug, sigvotatug vedotin, against a standard chemotherapy, docetaxel, in people with advanced non-small cell lung cancer that has spread or can't be removed. The drug is designed to stick to cancer cells and kill them. About 700 adults who have…

This study tests whether a combination of two drugs, amivantamab and lazertinib, works better than the current standard drug osimertinib for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer). About 1,074 participants who have not had pr…

This early-phase study tests a new drug (DKY709) alone or with another drug (PDR001) in adults with advanced solid tumors like lung cancer, melanoma, and breast cancer that have not responded to standard treatments. The main goal is to check safety and find the right dose. About …

This study looks at how well the drug osimertinib combined with chemotherapy works as the first treatment for people with advanced EGFR-mutant non-small cell lung cancer. It involves 532 adults with stage IIIB, IIIC, or IV disease who have not had prior therapy. The goal is to me…

This study aimed to test a combination of chemotherapy and radiation for people with advanced non-small cell lung cancer that could not be removed by surgery. The treatment included chemotherapy before, during, and after radiation. However, the study was withdrawn before any part…

This early-stage study tests a new drug (lazertinib) alone or with another drug (amivantamab) in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). The main goals are to find safe doses and check for side effects. About 700 partici…

This study tests a new drug, MK-3475, added to standard chemotherapy (gemcitabine) in people with advanced non-small cell lung cancer who have already tried other treatments. The goal is to find the safest dose and see if the combination helps control the cancer. Sixteen particip…

This study tests a new drug, repotrectinib, against the current standard crizotinib in people with a specific type of advanced lung cancer (ROS1-positive NSCLC) who have not had targeted therapy before. About 190 participants will be randomly assigned to one of the two pills. The…

This study tests whether combining two drugs, amivantamab and docetaxel, is safe and effective for people with advanced non-small cell lung cancer that has spread. It involves 12 adults whose cancer worsened after standard treatments. The goal is to find the best dose and see if …

This study tests whether adding a short, high-dose radiation boost to the main lung tumor, along with the immunotherapy drug durvalumab, is safe and effective for people with stage III non-small cell lung cancer after standard chemoradiation. About 6 participants will receive thi…

This study tests an oral drug called TAK-788 (mobocertinib) in adults with non-small cell lung cancer. The goal is to find the best dose, check safety, and see if it shrinks tumors. About 334 participants will take the drug daily, with or without chemotherapy, and continue as lon…

This study tests whether adding the immunotherapy drug durvalumab to standard radiation therapy can help control early-stage non-small cell lung cancer that cannot be surgically removed. About 724 adults with stage I or II lung cancer will receive either durvalumab or a placebo a…

This trial aimed to test a new treatment for people with metastatic non-small cell lung cancer. It used a patient's own immune cells (TILs) that were edited with CRISPR to remove a gene called CISH, potentially making them better at fighting cancer. The study was withdrawn before…

This study is for people with advanced solid tumors (like lung or colorectal cancer) that have a specific genetic change called KRAS G12C. It tests a new drug, JDQ443, combined with other treatments to see if they are safe and can shrink tumors. About 74 adults will take part. Th…

This study tests whether taking alectinib pills for two years after lung cancer surgery works better than standard chemotherapy at keeping the cancer from coming back. It includes 257 adults with a specific genetic type (ALK-positive) of non-small cell lung cancer that was comple…

This study tests whether adding the drug amivantamab to standard chemotherapy helps people with a certain type of advanced lung cancer (EGFR Exon 20ins) live longer without their cancer growing. About 308 participants receive either the combination or chemotherapy alone. The goal…

This early-stage study tests a new oral medication, PF-07985045, alone or with other cancer drugs, in people with advanced solid tumors that have a KRAS gene mutation. The cancers studied include non-small cell lung, colorectal, and pancreatic cancers. The main goals are to check…

This study tests an experimental drug called AZD7789 in people with advanced lung, stomach, or gastroesophageal cancer that has spread. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to check safety and see if the drug…

This study tests whether giving dexamethasone, montelukast, or methotrexate before an amivantamab infusion can reduce or prevent infusion-related reactions in people with advanced non-small cell lung cancer. The trial enrolled 68 participants who had previously taken osimertinib.…

This study looks at whether special skin care can lower the chance of skin problems like rashes and nail issues in people with advanced lung cancer who are taking a combination of two drugs (amivantamab and lazertinib). About 305 participants will be randomly assigned to differen…

This study looks at whether educating doctors in small and mid-sized city hospitals about standard guidelines helps improve testing and treatment for people with advanced non-small cell lung cancer. About 1000 patients will be observed to see if more get the right molecular tests…

This research study aims to learn more about how chest cancers like lung cancer, thymus cancer, and mesothelioma develop and spread. Researchers will collect blood, tumor tissue, and other fluids from 1,000 adult participants to look for biological markers. The goal is to find cl…

This study looks at how the immune system changes in people with stage III non-small cell lung cancer after they receive chemotherapy with radiation followed by the drug durvalumab. The goal is to find markers that could predict how well the treatment works. About 45 adults will …

This study looks at whether a special decision-making tool can help doctors and patients with advanced non-small cell lung cancer choose more wisely about continuing or stopping cancer treatments. The goal is to see if using this tool reduces the number of patients receiving aggr…

This study follows 1,200 people in China newly diagnosed with advanced non-small-cell lung cancer (stage IIIB/IIIC/IV) that cannot be removed by surgery. Researchers will collect information from medical records and follow patients over time to see what treatments doctors use, ho…